Featured Press Releases

New EpiVax Study Uncovers the Role of Treg Epitopes (Tregitopes) in Antibody Maturation: Implications for Therapeutic Antibodies

New EpiVax Study Uncovers the Role of Treg Epitopes (Tregitopes) in Antibody Maturation: Implications for Therapeutic Antibodies

AIM ImmunoTech announces the release of the next CEO Corner segment

AIM ImmunoTech announces the release of the next CEO Corner segment

  • 29 Jul 2024

AIM ImmunoTech Inc. announced the next CEO Corner segment has been published on the Company’s...

Biolexis Therapeutics reports positive outcomes for BLX-7006 in an expanded Diet-Induced Obesity (DIO) model study

Biolexis Therapeutics reports positive outcomes for BLX-7006 in an expanded Diet-Induced Obesity (DIO) model study

Actinium Pharmaceuticals publishes Actimab-A + CLAG-M trial results for relapsed/refractory AML in Leukemia

Actinium Pharmaceuticals publishes Actimab-A + CLAG-M trial results for relapsed/refractory AML in Leukemia

Glenmark Pharmaceuticals Launches Vancomycin Hydrochloride for Injection in the U.S

Glenmark Pharmaceuticals Launches Vancomycin Hydrochloride for Injection in the U.S

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ Subcutaneous Maintenance Dose for Early Alzheimer

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ Subcutaneous Maintenance Dose for Early Alzheimer's Treatment

Therapeutics Complement Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy Secondary to AMD

Therapeutics Complement Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy Secondary to AMD

  • Complement Therapeutics
  • 08 Oct 2025
Zifo Executive: Biopharma Faces AI Anxiety and Tech Obsolescence

Zifo Executive: Biopharma Faces AI Anxiety and Tech Obsolescence

  • Zifo Technologies
  • 07 Oct 2025
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ Subcutaneous Maintenance Dose for Early Alzheimer

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ Subcutaneous Maintenance Dose for Early Alzheimer's Treatment

  • Eisai Inc.
  • 07 Oct 2025
CareDx Announces IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE®

CareDx Announces IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE®

  • CareDx, Inc.
  • 06 Oct 2025
Niagen Bioscience

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Are Now Available at Over 50 iCRYO Clinics and More Than 900 Clinics Nationwide

  • Niagen Bioscience, Inc
  • 01 Oct 2025
Novartis Receives FDA Approval for Rhapsido® (remibrutinib), the First Oral, Targeted BTKi Treatment for Chronic Spontaneous Urticaria (CSU

Novartis Receives FDA Approval for Rhapsido® (remibrutinib), the First Oral, Targeted BTKi Treatment for Chronic Spontaneous Urticaria (CSU

  • Novartis Pharmaceuticals Corporation
  • 01 Oct 2025

Most Popular
October   2025
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.